参考文献/References:
[1]HORIKAWA A,MIYAKOSHI N,HONGO M,et al.The effects of trends in osteoporosis treatment on the incidence of fractures[J].Journal of Osteoporosis,2021,46(8):341-344.
[2]OH HS,KIM SK,SEO HY.Characteristics of osteoporosis & osteoporotic fractures in korea based on health insurance review and assessment (HIRA) database:2009-2017[J].Healthcare,2021,9(3):45-50.
[3]崔馨文,李翠娟,巩振东.中医药基于信号传导通路防治骨质疏松症的现代研究进展[J].陕西中医药大学学报,2016,39(5):120-123.
[4]SONG SS,GUO YY,YANG YH,et al.Advances in pathogenesis and therapeutic strategies for osteoporosis.[J].Pharmacology & therapeutics,2022,23(7):134-139.
[5]YU X,HOU L,GUO J,et al.Combined effect of osteoporosis and poor dynamic balance on the incidence of sarcopenia in elderly Chinese community suburban-dwelling individuals.[J].The journal of nutrition,health & aging,2020,24(1):71-77.
[6]贺洁,王拥军,朱莲,等.社区综合干预骨质疏松症多元效果评估的初探[J].上海预防医学,2021,33(4):306-10.
[7]何伟.从肝脾肾及其体用关系论原发性骨质疏松症的中医病机[J].陕西中医药大学学报,2018,41(5):10-13.
[8]侯伟,杜斌.中医药治疗骨质疏松症的研究进展[J].世界中西医结合杂志,2021,16(10):1956-1960.
[9]马远征,王以朋,刘强,等.中国老年骨质疏松症诊疗指南(2018)[J].中国骨质疏松杂志,2018,24(12):1541-1567.
[10]贺丽英,孙蕴,要文娟,等.2010—2016 年中国老年人骨质疏松症患病率Meta分析[J].中国骨质疏松杂志,2016,22(12):1590-1596.
[11]CHAI H,GE J,LI L,et al.Hypertension is associated with osteoporosis:a case-control study in Chinese postmenopausal women[J].BMC musculoskeletal disorders,2021,22(1):253.
[12]薛世宇,苏宏泉.中医辨体保健教育对社区老年人OP高危人群体质的影响[J].光明中医,2020,35(14):2130-2132.
[13]邱林杰,付燕来,杲春阳,等.基于中医养生理论探讨传统功法对绝经后骨质疏松症的防治[J].陕西中医药大学学报,2022,45(2):57-61.
[14]KANIS JA,HARVEY NC,MCCLOSKEY E,et al.Algorithm for the management of patients at low,high and very high risk of osteoporotic fractures[J].Osteoporosis international:a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,2020,31(1):1-12.
[15]CHADHA M,CHADDHA R,DIVAKAR H,et al.Osteoporosis:Epidemiology,Pathogenesis,Evaluation and Treatment[J].Open Journal of Orthopedics,2022,12(4):30.
[16]SIRIS ES,BAIM S,NATTIV A.Primary care use of FRAX:absolute fracture risk assessment in postmenopausal women and older men[J].Postgraduate Medicine,2010,122(1):82-90.
[17]FRANIC D.Risk factors for osteoporosis in postmenopausal women — from the point of view of primary care gynecologist[J].ZdraVstveno varstvo,2018,57(1):33-38.
[18]宁金月,贾玉凤,王燕,等.自拟中药壮肾补骨方辅助治疗绝经后骨质疏松症的疗效及血清性激素和骨代谢指标变化[J].山东医药,2022,62(29):74-77.
[19]董琪,刘德玉,昝强,等.“关中李氏骨伤流派”刘德玉教授从虚、瘀论治骨质疏松症的学术经验[J].陕西中医药大学学报,2021,44(6):15-18.
[20]温经渊,曾晗冰,吴连国.骨质疏松症中医辨证分型研究进展[J].安徽中医药大学学报,2021,40(5):101-104.
[21]LI JY,SUN K,QI BY,et al.An evaluation of the effects and safety of Zuogui pill for treating osteoporosis:Current evidence for an ancient Chinese herbal formula.[J].Phytotherapy research:PTR,2020,35(4).345-348.
[22]张蕴颖,吴大华,杨玲玲.仙灵骨葆胶囊联合常规西药治疗老年骨质疏松症临床研究[J].新中医,2022,54(3):108-112.
[23]王怀泽,刘陆晨,王峰.基于肾主骨运用膏方治疗骨质疏松症用药规律及临床研究[J].陕西中医药大学学报,2018,41(6):42-45.
[24]白璧辉,谢兴文,许伟,等.谢兴文主任医师从“三脏一体观”论治原发性骨质疏松症临床经验[J].陕西中医药大学学报,2018,41(2):18-20.
[25]许惠娟,李生强,陈娟,等.绝经后骨质疏松症不同年龄段中医证型分布特点[J].中国实验方剂学杂志,2017,23(12):157-161.
[26]邱峰,张贤,尹恒,等.老年性骨质疏松症中医证候分布规律研究[J].广州中医药大学学报,2021,38(4):651-655.
[27]黄菊.苁归益肾颗粒治疗2型糖尿病合并骨质疏松症患者的临床研究[D].合肥:安徽中医药大学,2017.
[28]李钊.男性骨质疏松症与内皮素的相关性研究[D].广州:广州中医药大学,2005.
[29]付丽霞.围绝经期女性雌二醇和卵泡刺激素水平与骨密度的关系[J].中国医学创新,2020,17(34):54-57.
[30]黄佳涌,郑博,胡良聪,等.血清睾酮水平与老年男性骨质疏松性髋部骨折的相关性[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):362-368.